Form 4/A for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2023-03-31 00:00:00 ET · period of report 2023-03-02 · accession 0001787306-23-000025 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DA	2023-03-31	2023-03-02	ARQT	Watanabe Todd Franklin	See Remarks, Dir	A - Grant	$0.00	+87.5K	456.6K	+24%	$0
DA	2023-03-31	2023-03-02	ARQT	Watanabe Todd Franklin	See Remarks, Dir	A - Grant	$0.00	+232.0K	232.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-03-02	A	A	87,500	$0.00	456,592	D	—	—	(F1) Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, 25% of the RSUs vest annually on March 2 of each year, beginning on March 2, 2024, subject to the Reporting Person's continued service to the Issuer. (F2) Reflects amount of securities beneficially owned as of March 2, 2023.
2	Derivative	Stock Option (right to buy)	2023-03-02	A	A	232,000	$0.00	232,000	D	$15.82 · — to 2033-03-02	232,000 Common Stock	(F3) Amendment filed to add RSUs and Stock Options granted to Reporting Person on March 2, 2023. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 2, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.